Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer

Cancer Gene Therapy

Volumn 7, Issue 4, 2000, Pages 574-580

  Candotti, Fabio ^a   Agbaria, Riad ^b   Mullen, Craig A ^a   Touraine, Renaud ^a   Balzarini, Jan ^c   Johns, David G ^b   Blaese, R Michael ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

(E) 5 (2 bromovinyl) 2' deoxyuridine; Ganciclovir; Gene therapy; Retroviral vector; Suicide gene

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; GANCICLOVIR; KANAMYCIN KINASE; NEOMYCIN; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; FUSION GENE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SUICIDE GENE;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0034034314     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700153     Document Type: Article

References (31)

1. Blaese RM, Mullen CA, Ramsey WJ. Strategies for gene therapy. Pathol Biol. 1993;41:672-676.
2. Blaese RM, Ishii-Morita H, Mullen CA, et al. In situ delivery of suicide genes for cancer treatment. Eur J Cancer. 1994;30A:1190-1193.
3. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990;82:297-300.
4. Huber BE, Richards CA, Krenitsky TA. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA. 1991;88:8039-8043.
5. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA. 1992;89:33-37.
6. Mroz PJ, Moolten FL. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum Gene Ther. 1993;4:589-595.
7. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1994; 1:233-238.
8. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther. 1994;5:969-978.
9. Mar EC, Chiou JF, Cheng YC, Huang ES. Inhibition of cellular DNA polymerase α and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J Virol. 1985;53:776-780.
10. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem. 1993;268:6332-6337.
11. Singhal S, Kaiser LR. Cancer chemotherapy using suicide genes. Surg Oncol Clin N Am. 1998;7:505-536.
12. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3:1354-1361.
13. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083-1092.
14. Balzarini J, Bohman C, Walker RT, De Clercq E. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol Pharmacol. 1994;45:1253-1258.
15. Schwartz F, Maeda N, Smithies O, et al. A dominant positive and negative selectable gene for use in mammalian cells. Proc Natl Acad Sci USA. 1991;88:10416-10420.
16. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 1990;18:3587-3596.
17. Bender MA, Palmer TD, Gelinas RE, Miller AD. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J Virol. 1987;61: 1639-1646.
18. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol. 1986;6:2895-2902.
19. Restifo NP, Esquivel F, Asher AL, et al. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J Immunol. 1991;147:1453-1459.
20. Reiss B, Sprengel R, Will H, Schaller H. A new sensitive method for qualitative and quantitative assay of neomycin phosphotransferase in crude cell extracts. Gene. 1984;30: 211-217.
21. Agbaria R, Mullen CA, Hartman NR, et al. Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction. Mol Pharmacol. 1994;45:777-782.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
23. Kozak M. The scanning model for translation: an update. J Cell Biol. 1989;108:229-241.
24. Human gene marker/therapy protocols. Hum Gene Ther. 1998;9:2805-2852.
25. Wu X, Holschen J, Kennedy SC, Ponder KP. Retroviral vector sequences may interact with some internal promoters and influence expression. Hum Gene Ther. 1996;7:159-171.
26. Yee JK, Moores JC, Jolly DJ, Wolff JA, Respess JG, Friedmann T. Gene expression from transcriptionally disabled retroviral vectors. Proc Natl Acad Sci USA. 1987;84: 5197-5201.
27. Chen BF, Hsieh CL, Chen DS, Hwang LH. Improved gene expression by a U3-based retroviral vector. Biochem Biophys Res Commun. 1992;184:330-337.
28. Lupton SD, Brunton LL, Kalberg VA, Overell RW. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol. 1991;11:3374-3378.
29. Loimas S, Wahlfors J, Janne J. Herpes simplex virus thymidine kinase-green fluorescent protein fusion gene: new tool for gene transfer studies and gene therapy. Biotechniques. 1998;24:614-618.
30. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
31. Balzarini J, De Clercq E, Ayusawa D, Seno T. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. FEBS Lett. 1985;185:95-100.